The 41st Annual Meeting of the Japanese Society for the Study of Xenobiotics in Tsukuba

Message from the Chair

We are pleased to announce that the 41st Annual Meeting of the Japanese Society for the Study of Xenobiotics (JSSX) will be held over four days, from Monday, November 16 to Thursday, November 19, 2026, at the TSUKUBA International Congress Center, located in the heart of the Tsukuba Science City. This is the second time that the annual JSSX meeting will be held in Tsukuba City, following the 2019 event before the COVID-19 pandemic, and we are delighted to once again host our conference in this city renowned as a hub of science and technology.

DMPK science covers a broad spectrum of scientific fields, from basic research to clinical application and regulatory science, and is widely recognized to play a key role in understanding the systemic disposition of pharmaceuticals at the molecular and genetic levels, based on a wide range of approaches including the highly sensitive quantitative and specific qualitative bioanalysis, and also in bridging and verifying the relationship between efficacy, safety, and concentration within the body based on mathematical models in order to quantitatively predict therapeutic effects and adverse event risks in humans. Although DMPK science has grown remarkably with the advanced knowledge across related research areas and the innovative evolution of cutting-edge technologies, the increasing diversity of drug discovery modalities highlights the importance of further emerging challenges in DMPK/PD research.

The theme for this annual meeting is "Shu-Ha-Ri/In-On-Out: New paradigm in ADMET sciences pioneering the unknown path of the future". In recent years, the scope for DMPK scientist has been expanding at an accelerating pace along with the expansion and implementation of new technological platforms, such as the FDA-promoted NAMs, in the drug development. Through the exchange of cutting-edge insights and discussions among scientists with the diverse expertise and backgrounds from industry, government, and academia worldwide, we expect to have an opportunity to explore the direction of emergent innovation and the collaborative research as well as the potential for new scientific methodologies and technological/product development in the future DMPK research, leading to contribute to patient benefits in new drug development.

We are committed to making this annual meeting a stimulating and rewarding experience for all participants engaged in DMPK research. Your continued support and cooperation in the planning and execution of this conference are greatly appreciated, and we look forward to welcoming as many participants as possible.

With warm regards,

December 2025

Takafumi Komori, Ph.D.
Chair, 41th Annual Meeting of the Japanese Society for the Study of Xenobiotics (JSSX)
Biopharmaceutical Assessment, Deep Human Biology Learning, Eisai Co., Ltd.